Viatris Gmbh & Co Kg

Arzneimittelwerk Dresden Gmbh

Wolfgang Sauer

Gunter Laban

Reni Bartsch

Dieter Lohmann

Annegret Jannasch

Hildegard Poppe

Angelika Rostock

Gottfried Faust

Hans-Joachim Jansch

Alexandr P Skoldinov

Natalja V Kaverina

Valentin V Lyskovzev

Michael Müller

Christine Siegemund

Yekaterina A Talmachova

Gennadi G Chichkanov

Alwina W Stawrowskaya

Carla Ruger

Arkadij M Lichoserstov

Yekaterina K Grigoryeva

The invention relates to a method for the production of (R)- or (S)-8-chloro-6-hydroxyoctanoic acid alkyl esters of the general formula (R)-II or (S)-II in which R has the meaning C-alkyl, from 8-chloro-6-oxooctanoic acid alkyl esters of the general formula I in which R has the above meaning, by enzymatic reduction using alcohol dehydrogenases, such asor, in the presence of cofactor regeneration systems. The resulting (R)- and (S)-8-chloro-6-hydroxyoctanoic acid esters can be converted in a known manner into (R)-&#x3b1;-lipoic acid and (S)-&#x3b1;-lipoic acid, respectively.

Method for the production of (r)- and (S)-8-chloro-6-hydroxyoctanic acid alkyl esters by enzymatic reduction

The invention relates to new modifications of the trometamol salt of R-thioctic acid of the formula I,processes for their production, pharmaceutical preparations containing these modifications, and their medical application.

Modifications of the trometamol salt of R-thioctic acid as well as a process for their production

5-(w-Aminoacyl)-5,10-dihydro-11H-dibenzo(b,e)(1,4)-diazepine-11-ones, and their preparation are disclosed for treatment of antiarrhythmia and as an anticholinergic drug.

5-(1-aminoacyl)-5,10-dihydro-11H-dibenzo[b,e](1,4)diazepin-11-ones

The substituted 5-(phenoxyalkanoylamino)-uracil compounds have the following formula I: ##STR1## wherein R.sub.1 and R.sub.2 are each independently hydrogen; a branched or linear alkyl group having 1 to 6 carbon atoms; a branched or straight chain alkenyl or alkynyl group having 1 to 6 carbons atoms; a cycloalkyl group having from 3 to 7 carbon atoms or a cycloalkylmethyl group having a cycloalkyl residue of 3 to 7 carbon atoms; or a phenylalkyl group having an alkyl residue having from 1 to 3 carbon atoms and a phenyl residue, the phenyl residue being unsubstituted or having a halogen, methoxy, methyl or trifluoromethyl substituent; R.sub.3 is a hydrogen, methyl or amino groups; R.sub.4 is halogen, methoxy or methyl groups, and n is 1 or 2. Pharmaceutical compositions for treating cerebrovascular, neuronal-degenerative and senility-induced disorders associated with learning, memory and cognitive dysfunctions are described which contain a therapeutically effective amount of the substituted 5-(phenoxyalkanoylamino)-uracil in a pharmaceutically acceptable carrier.

Substituted 5-(phenoxyalkanoylamino)-uracil compounds, methods for

Growing community of inventors

Dresden, Germany

Wolfgang Sauer